The application belongs to the technical field of biological
medicine, and particularly relates to application of (E)-BCI
hydrochloride in preparation of a
medicine for treating
sepsis. The application provides application of (E)-BCI
hydrochloride in preparation of the
medicine for treating
sepsis. (E)-BCI
hydrochloride regulates a DRD1
gene through targeting, quiets an
interferon stimulation
storm, reduces abnormal activation of astrocytes, reduces a level of an inflammatory factor, improves expression of a
nerve activity gene, and provides a non-antibiotic dependent medicine for
sepsis treatment from a new target point of regulating
inflammation and immune balance, and is particularly suitable for
systemic inflammatory response syndrome caused by various causes such as infection, operation and trauma, and has a wide clinical application prospect.